Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence”
Crossref DOI link: https://doi.org/10.1007/s12325-021-01694-x
Published Online: 2021-04-29
Published Print: 2021-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Finck, Barbara http://orcid.org/0000-0002-7913-767X
Geller, Robert B.
Walden, Paul
Funding for this research was provided by:
Coherus BioSciences (No award number)
Text and Data Mining valid from 2021-04-29
Version of Record valid from 2021-04-29
Article History
Received: 10 December 2020
Accepted: 3 March 2021
First Online: 29 April 2021